Full Fed. Circ. Won't Review $20M Cialis Marketing Verdict
By Kevin Penton ( February 6, 2019, 3:22 PM EST) -- The full Federal Circuit on Tuesday declined to review whether a panel erred by upholding a $20 million infringement verdict entered in Texas federal court against Eli Lilly & Co. for marketing its erectile dysfunction drug Cialis to also treat enlarged prostates....
Law360 is on it, so you are, too.
A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.
A Law360 subscription includes features such as
- Daily newsletters
- Expert analysis
- Mobile app
- Advanced search
- Judge information
- Real-time alerts
- 450K+ searchable archived articles
And more!
Experience Law360 today with a free 7-day trial.